Effective anti-programmed death-1 therapy in a SUFU-mutated patient with Gorlin-Goltz syndrome

Moreira A, Kirchberger MC, Toussaint F, Erdmann M, Schuler G, Heinzerling L (2018)

Publication Type: Journal article

Publication year: 2018

Journal

British Journal of Dermatology Wiley-Blackwell

DOI: 10.1111/bjd.16607

Abstract

We present the case of a 77-year-old male patient with more than 50 basal cell carcinomas on the head and upper trunk. The patient did not respond to several lines of treatment, including surgery, imiquimod, retinoids, itraconazole and therapy with the hedgehog inhibitor vismodegib. The patient responded well to off-label therapy with the anti-programmed death-1 antibody pembrolizumab after four infusions.

Authors with CRIS profile

Alvaro Moreira Department of Dermatology Frédéric Toussaint Department of Dermatology Gerold Schuler Lehrstuhl für Haut- und Geschlechtskrankheiten Lucie Heinzerling Department of Dermatology

How to cite

APA:

Moreira, A., Kirchberger, M.C., Toussaint, F., Erdmann, M., Schuler, G., & Heinzerling, L. (2018). Effective anti-programmed death-1 therapy in a SUFU-mutated patient with Gorlin-Goltz syndrome. British Journal of Dermatology. https://doi.org/10.1111/bjd.16607

MLA:

Moreira, Alvaro, et al. "Effective anti-programmed death-1 therapy in a SUFU-mutated patient with Gorlin-Goltz syndrome." British Journal of Dermatology (2018).

BibTeX: Download